Dynamic personalized tests provide clinicians with early actionable data from the patient’s own biological message systems.


One test, one RNA Signature with strong performance on all clinical metrics.

Edge Precision.

Artificial intelligence-assisted analysis of selected signals provides the most relevant information for ALL transplant patients.

previous arrow
next arrow

What we do

Verici Dx commercializes RNA signatures based tests to decipher the body’s clinical messages to provide data driven insights to clinicians their patients. Currently we are validating a complementary suite of leading-edge tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes.

The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. 

The Company also has a mission to accelerate the pace of innovation by research using the fully characterized data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners. We are singularly focused on providing insights that informs the path to overall graft survival and successful outcomes for patients.

Who we are

We believe in the diagnostic power of RNA signatures to bring substance to the promise of personalized medicine. We hold ourselves to the highest of standards and are proud to be supported by a strong foundation of core values. These values guide us and push us through the rigors of science and precision to deliver the data-driven answers clinicans and their patients deserve.
Who we are
Driven by curiosity.
Delivered by science.

Latest News

CLIA Certificate of Compliance update

US clinical laboratory now fully accredited in 49 states Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that further to the RNS dated 2 March 2023, the Company has received compliance authorisation for the operation of its commercial clinical laboratory testing in respect of samples from an additional […]
Keep Reading
1 2 3 65
See All News